{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:58:14Z","timestamp":1783090694840,"version":"3.54.6"},"reference-count":30,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Rosacea is a skin condition characterised by persistent facial erythema, flushing, papules, pustules, and telangiectasia. Botulinum toxin A (BoNT-A) has been used to treat a variety of conditions, but its effectiveness in improving facial erythema in rosacea patients is uncertain.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>The aim of the study is to evaluate the effectiveness and determine the optimal dose of BoNT-A treatment for rosacea.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>An online database search (Pubmed, Cochrane Library and Embase) was conducted on 30<jats:sup>th<\/jats:sup> June 2023 to identify studies that used intradermal injection of BoNT-A to treat facial erythema in rosacea patients and excluded studies in which BoNT-A was used for facial erythema due to other known medical condition such as menopause, drug or pregnancy. The primary outcome measure for this study was the improvement in erythema score as objectively assessed. A random effect model was used in the meta-analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Seven studies involving a total of 167 rosacea patients were included in the meta-analysis. Meta-analysis of two randomised controlled trials showed improvement of erythema on the third month after treatment standardized mean difference (SMD): 1.676, 95% confidence interval (CI): 2.278\u20131.074, I<jats:sup>2<\/jats:sup>: 35.76%). A separate analysis of seven single-armed treatment studies found significant improvement in erythema with intradermal injection of BoNT-A at one, two and three months after treatment (first month: SMD: 2.712, 95% CI: 4.1182\u20131.243; second month: SMD:2.213, 95% CI: 3.702\u20130.725; third month: SMD: 1.912, 95% CI: 2.882\u20130.941). Adverse events, including mild facial paralysis and injectional purpura, were reported in some studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Limitation<\/jats:title>\n<jats:p>The limitations of this study include heterogeneity in study design and a small sample size.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Intradermal injection of BoNT-A may be an effective treatment for facial erythema in rosacea. Unwanted facial muscle paralysis was seen in different BoNT-A concentration but not noted when the dose was less than 0.02ml per site. Future studies particularly randomised trials are required to identify the volume of injection required to reduce the erythema<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_274_2024","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:29:26Z","timestamp":1736335766000},"page":"448-454","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Intradermal injection of botulinum toxin for erythema in rosacea: A scoping review and meta-analysis"],"prefix":"10.25259","volume":"91","author":[{"given":"Marvin Chia-Han","family":"Yeh","sequence":"first","affiliation":[{"name":"Department of Dermatology, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chu","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Radiology, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"10.25259\/IJDVL_274_2024\/ref-1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: The 2017 update by the national rosacea society expert committee","volume":"78","author":"Gallo","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjd.15122","article-title":"Updating the diagnosis, classification and assessment of rosacea: Recommendations from the global ROSacea COnsensus (ROSCO) panel","volume":"176","author":"Tan","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/jdv.13748","article-title":"Feelings of stigmatization in patients with rosacea","volume":"31","author":"Halioua","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_274_2024\/ref-5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1080\/13548506.2013.841968","article-title":"Symptom severity and psychological sequelae in rosacea: Results of a survey","volume":"19","author":"B\u00f6hm","year":"2014","journal-title":"Psychol Health Med"},{"key":"10.25259\/IJDVL_274_2024\/ref-6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaad.2020.07.123","article-title":"Treatment approaches and outcomes associated with the use of abobotulinumtoxinA for the treatment of hyperhidrosis: A systematic review","volume":"85","author":"Galadari","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/toxins9120403","article-title":"Botulinum toxin in the field of dermatology: Novel indications","volume":"9","author":"Kim","year":"2017","journal-title":"Toxins (Basel)"},{"key":"10.25259\/IJDVL_274_2024\/ref-8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/CCID.S307013","article-title":"Use of botulinum toxin in treating rosacea: A systematic review","volume":"14","author":"Zhang","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.25259\/IJDVL_274_2024\/ref-10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/DSS.0000000000001819","article-title":"Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: A randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema","volume":"45","author":"Kim","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_274_2024\/ref-11","doi-asserted-by":"publisher","first-page":"1452.e1","DOI":"10.1016\/j.urology.2013.09.003","article-title":"Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical Onabotulinumtoxin A injections combined with hydrodistention for patients with interstitial cystitis\u2014clinical results and immunohistochemistry analysis","volume":"82","author":"Peng","year":"2013","journal-title":"Urology"},{"key":"10.25259\/IJDVL_274_2024\/ref-12","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1038\/sj.jid.5700429","article-title":"Neuropeptide control mechanisms in cutaneous biology: Physiological and clinical significance","volume":"126","author":"Peters","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.eururo.2008.05.007","article-title":"Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats","volume":"56","author":"Chuang","year":"2009","journal-title":"Eur Urol"},{"key":"10.25259\/IJDVL_274_2024\/ref-14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdermsci.2018.12.004","article-title":"Botulinum toxin blocks mast cells and prevents rosacea like inflammation","volume":"93","author":"Choi","year":"2019","journal-title":"J Dermatol Sci"},{"key":"10.25259\/IJDVL_274_2024\/ref-15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1524-4725.2008.34207.x","article-title":"The effect of botulinum toxin type A on full-face intense pulsed light treatment: A randomized, double-blind, split-face study","volume":"34","author":"Khoury","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_274_2024\/ref-16","first-page":"549","article-title":"A Pilot, double-blind, placebo-controlled study to assess the efficacy and safety of incobotulinumtoxinA injections in the treatment of rosacea","volume":"16","author":"Dayan","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-17","doi-asserted-by":"publisher","first-page":"e15395","DOI":"10.1111\/dth.15395","article-title":"A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea","volume":"35","author":"Tong","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_274_2024\/ref-18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1524-4725.2004.30017.x","article-title":"Botulinum toxin for the treatment of facial flushing","volume":"30","author":"Yuraitis","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_274_2024\/ref-19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/00042728-200504000-00023","article-title":"Re: Botulinum toxin for the treatment of facial flushing","volume":"31","author":"Kranendonk","year":"2005","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_274_2024\/ref-20","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1111\/j.1524-4725.2006.32372.x","article-title":"Successful use of botulinum toxin a for the treatment of neck and anterior chest wall flushing","volume":"32","author":"Alexandroff","year":"2006","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_274_2024\/ref-21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.5935\/scd1984-8773.20201243747","article-title":"Botulinum toxin for the treatment of erythema and flushing of rosacea with two different techniques: Intradermal injections and facial electroporation","volume":"12","author":"Herane","year":"2020","journal-title":"Surg Cosmet Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-22","first-page":"e76","article-title":"A new treatment regimen for rosacea: OnabotulinumtoxinA","volume":"11","author":"Dayan","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"Suppl 1","key":"10.25259\/IJDVL_274_2024\/ref-23","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/DSS.0000000000000277","article-title":"Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea","volume":"41","author":"Bloom","year":"2015","journal-title":"Dermatol Surg"},{"key":"10.25259\/IJDVL_274_2024\/ref-24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000368773","article-title":"Botulinum toxin for the treatment of refractory erythema and flushing of rosacea","volume":"230","author":"Park","year":"2015","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_274_2024\/ref-25","doi-asserted-by":"publisher","first-page":"688","DOI":"10.5021\/ad.2018.30.6.688","article-title":"A pilot study to evaluate the efficacy and safety of treatment with botulinum toxin in patients with recalcitrant and persistent erythematotelangiectatic rosacea","volume":"30","author":"Park","year":"2018","journal-title":"Ann Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-26","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/j.jaad.2018.05.014","article-title":"Mesotherapy with botulinum toxin for the treatment of refractory vascular and papulopustular rosacea","volume":"88","author":"Bharti","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-27","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s13555-022-00784-0","article-title":"Botulinum toxin A alleviates persistent erythema and flushing in patients with erythema telangiectasia rosacea","volume":"12","author":"Yang","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_274_2024\/ref-28","doi-asserted-by":"publisher","first-page":"e13976","DOI":"10.1111\/dth.13976","article-title":"Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing","volume":"33","author":"Al-Niaimi","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_274_2024\/ref-29","first-page":"42","article-title":"Botulinum toxin: An effective treatment for flushing and persistent erythema in rosacea","volume":"14","author":"Luque","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.25259\/IJDVL_274_2024\/ref-30","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1111\/jocd.14692","article-title":"Microbotox: A prospective evaluation of dermatological improvement in patients with mild-to-moderate acne and erythematotelangiectatic rosacea","volume":"21","author":"Calvisi","year":"2022","journal-title":"J Cosmet Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/intradermal-injection-of-botulinum-toxin-for-erythema-in-rosacea-a-scoping-review-and-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/intradermal-injection-of-botulinum-toxin-for-erythema-in-rosacea-a-scoping-review-and-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T06:32:02Z","timestamp":1750833122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/intradermal-injection-of-botulinum-toxin-for-erythema-in-rosacea-a-scoping-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":30,"alternative-id":["10.25259\/IJDVL_274_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_274_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"448"}}